Dr Reddy’s Lab launches public offer to acquire shares of OctoPlus N.V.

14 Dec 2012 Evaluate

Dr Reddy’s Laboratories together with its subsidiaries has launched the recommended public offer to acquire all the issued and outstanding shares of OctoPlus N.V, a service based specialty pharmaceutical company, at an offer price of EUR 0.52 cum dividend per share. The offer period commences on December 14, 2012 and ends on February 08, 2013, unless extended.

The shareholders including certain members of the boards holding in aggregate 63.5% of the issued and outstanding ordinary shares of OctoPlus have entered into irrevocable undertakings to tender their shares under the offer.

Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.

Dr. Reddys Lab Share Price

5784.50 -92.20 (-1.57%)
31-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1462.50
Dr. Reddys Lab 5784.50
Cipla 1451.25
Zydus Lifesciences 1001.15
Lupin 1587.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.